Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
J Control Release. 2012 Sep 28;162(3):591-8. doi: 10.1016/j.jconrel.2012.07.042. Epub 2012 Aug 6.
A new micelle drug carrier that consists of a diblock polymer of propylene sulfide (PS) and N,N-dimethylacrylamide (poly(PS₇₄-b-DMA₃₁₀)) has been synthesized and characterized for site-specific release of hydrophobic drugs to sites of inflammation. Propylene sulfide was first polymerized using a thioacyl group transfer (TAGT) method with the RAFT chain transfer agent (CTA) 4-cyano-4-(ethylsulfanylthiocarbonylsulfanyl) pentanoic acid (CEP), and the resultant poly(PS₇₄-CEP) macro-CTA was used to polymerize a second polymer block of DMA using reversible addition-fragmentation chain transfer (RAFT). The formation of the poly(PS₇₄-b-DMA₃₁₀) diblock polymer was confirmed by ¹H NMR spectra and gel permeation chromatography (GPC). Poly(PS₇₄-b-DMA₃₁₀) formed 100 nm micelles in aqueous media as confirmed by dynamic light scattering (DLS) and transmission electron microscopy (TEM). Micelles loaded with the model drugs Nile red and DiO were used to demonstrate the ROS-dependent drug release mechanism of these micelles following treatment with hydrogen peroxide (H₂O₂), 3-morpholinosydnonimine (SIN-1), and peroxynitrite. These oxidants were found to oxidize the micelle PPS core, making it more hydrophilic and triggering micelle disassembly and cargo release. Delivery of poly(PS₇₄-b-DMA₃₁₀) micelles dual-loaded with the Förster Resonance Energy Transfer (FRET) fluorophore pair DiI and DiO was used to prove that endogenous oxidants generated by lipopolysaccharide (LPS)-treated RAW 264.7 macrophages significantly increased release of nanocarrier contents relative to macrophages that were not activated. In vitro studies also demonstrated that the poly(PS₇₄-b-DMA₃₁₀) micelles were cytocompatible across a broad range of concentrations. These combined data suggest that the poly(PS₇₄-b-DMA₃₁₀) micelles synthesized using a combination of TAGT and RAFT have significant potential for site-specific drug delivery to tissues with high levels of oxidative stress.
一种由丙烯硫醚(PS)和 N,N-二甲基丙烯酰胺(聚(PS₇₄-b-DMA₃₁₀))组成的新型胶束药物载体已被合成并表征,用于将疏水性药物靶向递送到炎症部位。首先使用硫代酰基基团转移(TAGT)法,用 RAFT 链转移剂(CTA)4-氰基-4-(乙基硫代羰基硫代羰基)戊酸(CEP)聚合丙烯硫醚,所得聚(PS₇₄-CEP)大分子 CTA 用于使用可逆加成-断裂链转移(RAFT)聚合第二块 DMA 聚合物块。聚(PS₇₄-b-DMA₃₁₀)嵌段共聚物的形成通过 ¹H NMR 光谱和凝胶渗透色谱(GPC)得到证实。聚(PS₇₄-b-DMA₃₁₀)在水溶液中形成 100nm 的胶束,这一点通过动态光散射(DLS)和透射电子显微镜(TEM)得到证实。负载模型药物尼罗红和 DiO 的胶束用于证明这些胶束在过氧化氢(H₂O₂)、3-吗啉代-sydnonimine(SIN-1)和过氧亚硝酸盐处理后,基于 ROS 的药物释放机制。这些氧化剂被发现氧化胶束 PPS 核,使其更亲水,并触发胶束解体和货物释放。负载聚(PS₇₄-b-DMA₃₁₀)的胶束,其双载有Förster 共振能量转移(FRET)荧光团对 DiI 和 DiO,用于证明由脂多糖(LPS)处理的 RAW 264.7 巨噬细胞产生的内源性氧化剂显著增加了纳米载体内容物的释放,与未激活的巨噬细胞相比。体外研究还表明,聚(PS₇₄-b-DMA₃₁₀)胶束在广泛的浓度范围内具有细胞相容性。这些综合数据表明,使用 TAGT 和 RAFT 的组合合成的聚(PS₇₄-b-DMA₃₁₀)胶束在靶向递送到氧化应激水平高的组织方面具有显著的潜力。